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ABSTRACT 
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INTEGRATIVE –OMIC APPROACH 
 
 
Wendy M. Demos 
 
Marquette University, 2012 
 
 
Background: 
Hypoplastic left heart syndrome (HLHS) is a congenital heart defect that leads to 
neonatal death or compromised quality of life for those affected and their families. This syndrome 
requires extensive medical intervention for the affected to survive.  It is characterized by 
significant underdevelopment or non-existence of the components of the left heart and the aorta, 
including the left ventricular cavity and mass. There are many factors ranging from genetics to 
environmental relationships hypothesized to lead to the development of the syndrome, including 
recent studies suggesting a link between hearing impairment and congenital heart defects (CHD). 
Although broadly characterized those factors remain poorly understood.  The goal of this project 
is to systematically utilize bioinformatics tools to determine the relationships of novel mutations 
found in exome sequencing to a familial congenital heart defect. 
 
Methods 
A systematic genomic and proteomic approach involving exome sequencing, pathway 
analysis, and protein modeling was implemented to examine exome sequencing data of a patient 
with HLHS. Subsequent findings were examined in immediate family members and relatives to 
investigate inheritance and validate the relationship of novel variants to CHD in the family. 
 
Conclusions 
 A rare, novel mutation in the LAMA4 gene carried by the proband and other family 
members may contribute to the development of HLHS in this family.  
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CHAPTER 1. INTRODUCTION 
1.1 DNA Sequencing 
The ability of researchers to comprehensively examine disease etiology at the genomic 
level has been revolutionized by  the development of high throughput DNA sequencing 
technologies such as 454 pyrosequencing (Roche Diagnostics), HighSeq (Illuminia, Inc.), SOLiD 
(Applied Biosystems), and Ion semiconductor sequencing (Ion Torrent Systems Inc.) These 
technologies have drastically reduced DNA sequencing time and costs by generating massive 
quantities of data in a fraction of the time of traditional Sanger sequencing. Researchers and 
clinicians have capitalized on these technologies to further our understanding of the human 
genome and causes of disease. The field of ‘genomic medicine’, which utilizes the sequence of  
an individual’s exome (coding regions of genes) has transformed the capability of modern 
medicine to diagnose and prescribe personalized treatment methods.  
The chain terminator method of DNA sequencing (commonly referred to as the Sanger 
sequencing method) utilizes a DNA polymerase that adds nucleotides to generate a 
complementary strand of DNA to a single stranded DNA template. Applied Biosystems 
automated this type of DNA sequencing by creating machines that could run individual reactions 
in a single column rather than four simultaneous reactions on a polyacrylamide gel. These 
machines provided a visual readout of the DNA sequence called a chromatogram. At the onset of 
sequence automation a run of 24 samples would yield 12,000 bases of DNA per day (Adams 
2008). Currently the Applied Biosystems 3130xl can generate more than 121,600 bases per day. 
(Applied Biosystems). 
In comparison, pyrosequencing can yield 1,000,000,000 bases or 400,000 sequencing 
reads per run (Roche Diagnostics). Pyrosequencing is based on a method that measures the 
release of inorganic pyrophosphate, which is converted into visible light (Metzker 2005). A series 
of dNTPs are added to the reaction and a camera records emitted light after each round. The 
pattern of captured light is translated into the DNA sequence.  
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Unlike Sanger sequencing, 454 sequencing avoids the labor and time extensive step of 
cloning the DNA template into a vector. Roche 454 sequencing employs an emulsion PCR in 
which a single molecule of DNA binds to a single magnetic bead. Many beads are processed in a 
water and oil mixture which in turn isolates each bead into its own water droplet. The 
amplification process runs all beads in parallel and results in about 10 million clonal copies of a 
single DNA fragment, each bead holding a different fragment (Roche Diagnostics). This step 
alone vastly increases the starting quantity of DNA template over traditional Sanger sequencing.  
Filtering through the resulting 454 sequence data to find allelic variations that may be 
related to a specific phenotype is a daunting task.  The DNA Sequences returned from the exome 
sequencing reaction are aligned to a reference genome. This comparison aids in finding 
nucleotide differences from the patient sequence to the human genome reference sequence. These 
differences are termed variant. Some variants are not tolerated and presumably cause or 
contribute to the development of disease. A recent investigation of the case of a 15 month old 
male with a seemingly undiagnosable severe health condition supports the relationship of 
sequence variation to disease. Genomic DNA from the patient was subjected to whole exome 
sequencing. The sequencing reaction returned over 16,000 variants.  Due to the uncommon 
presentation of symptoms and condition bioinformaticians focused on variants not found in the 
general population (novel) to determine which changes in the patient DNA sequence may have 
been linked to the condition under investigation. This approach ultimately led to a definitive 
diagnosis the patient carries a rare mutation in an apoptotic suppressor protein (XIAP) resulting in 
immunodeficiency (Worthey et. al. 2011).  
Establishing prospective gene candidates and conducting the subsequent investigations is 
an extremely time consuming task as a result of the number of novel variants yielded by the 
sequencing method, future diagnosis, preventative measures, genetic testing, or advancements in 
treatment depend on an efficient approach to determine or rule out causal or contributory genes 
related to disease.  
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1.2 Congenital Heart Defects 
A congenital heart defect (CHD) is described as a structural condition present at birth that 
can affect the heart and the way it works. CHD can affect the interior walls and valves of the 
heart and the arteries and veins that carry blood to the heart and body (Knapp et. al. 2010). There 
are many types of congenital heart defects which can be asymptomatic or complex with life-
threatening symptoms (NHLBI). CHD affects 1 in 100 live births and is considered one of the 
most common types of birth defects. The incidence of moderate to severe forms is approximately 
1% of the newborn population (Hoffman 1995, Hoffman et. al. 2002, Sander et. al. 2006).  From 
1999 to 2006, there were 41,494 CHD-related deaths and 27,960 deaths resulting from CHD in 
the United States (Gilboa et. al. 2010).   
A sub category of CHD is critical congenital heart defect (CCHD). CCHD is a group of 
ductal dependent defects that cause severe and life-threatening symptoms that require 
intervention within the first year of life (Knapp et. al. 2010, Chang et. al. 2008, CDC).Failure to 
intervene within the first few days of life results in a fatal outcome (Barron et. al. 2009). The 
seven defects that are categorized as CCHD (Table 1) represent about 17-31% of all congenital 
heart defects (Knapp et. al. 2010). 
Seven Defects Categorized as CCHD 
Hypoplastic left heart syndrome  Total anomalous pulmonary venous return  
Pulmonary atresia (with intact septum)  Transposition of the great arteries 
Tetralogy of Fallot Tricuspid atresia 
Truncus arteriosus   
Table 1. Types of CCHD. The seven types of CCHD according to the CDC in the context of 
newborn screening using pulse oximetry (Data retrieved from: 
http://www.cdc.gov/ncbddd/pediatricgenetics/pulse.html) 
 
1.3Hypoplastic Left Heart Syndrome 
Hypoplastic left heart syndrome (HLHS) is a classification of CCHD that refers to 
cardiac malformations characterized by significant underdevelopment or non-existence of the 
components of the left heart and the aorta, including the left ventricular cavity and mass 
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(Tchervenkov et. al. 2006). The left heart is responsible for moving oxygenated blood to the aorta 
which then carries and distributes it to the rest of the body (Fogoros 2003). Defects in this system 
can be severely debilitating and / or fatal to affected individuals. 
Until recently, survival of the first five years of life in a person diagnosed with HLHS 
ranged between 50% and 69%.  With improved diagnostics and management it is now expected 
that 70% of HLHS patients will survive into adulthood (Feinstein et. al. 2012). Motor or cognitive 
delays characterized by impaired social skills, hampered core communications skills, impulsive 
behavior, and among other related symptoms are associated to HLHS. Patients, parents, and 
clinicians affected by HLHS have participated in surveys to measure their and the affected 
individual’s perceived quality of life. Findings have been inconsistent due to methodology of 
studies and the stress of dealing with a chronic illness (Feinstein et. al. 2012). 
HLHS is described as a genetically inherited syndrome although a definitive method of 
inheritance has not yet been defined. The prevalence of HLHS is not linked to any race or gender; 
however, males are twice as commonly affected as females (Stumper 2010, CDC 2007). It is 
known there is an increased frequency in relatives of patients with HLHS to also be affected 
(Loffredo 2000, Lewin et. al. 2004). 55% of families had more than 1 affected family member 
and the recurrence rate for HLHS among siblings is 8% (Grossfeld 2007) 
The etiology of HLHS has broadly been studied and the consensus is that the syndrome 
has multifactorial causes (Sander et. al. 2006). Linkage analysis suggesting genetic heterogeneity, 
mutations at multiple genetic loci, seasonal effects, chromosomal disorders, and environmental 
conditions also have been described as potential modes of the development of HLHS (Eghtesady 
et. al. 2011, Grossfeld 2007, Grossfeld 1999, McBride et. al. 2008, Aberdam et. al.2002). The 
hypothesis of multiple genetic loci is further supported by the strong association of HLHS with 
conditions such as Trisomy 13, Trisomy 18, Turner syndrome, and Jacobson syndrome 
(Grossfeld et. al. 2009).  
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1.4 Objective 
At this time there is no gold standard or pipeline to manage these data and rapidly 
determine specific variations in relation to the disease under investigation. The goal of this thesis 
is to execute a systematic and efficient approach that incorporates genomic and proteomic 
analysis to investigate genomic variants found in exome sequencing of a patient (proband) with 
HLHS. This approach will incorporate the use of bioinformatic tools to: design PCR primers, 
align DNA sequences, determine mutation effects, conduct pathway analysis, and construct 
protein models with laboratory methods such as PCR to narrow the study set of genes and 
ultimately determine the path of inheritance and potential relationship of the novel variant or 
variants to CHD. 
A mutation was found in the LAMA4 gene of the proband. The application of the 
described process provides evidence suggesting a potential causal or contributory relationship in 
regards to the development of HLHS in this family. Based on previous research that HLHS is a 
mutligeneic syndrome and the family history, the relationship of LAMA4 and GJB2 will also be 
investigated to determine if together they are linked to the development of HLHS in this family. 
1.5 Outline of Thesis 
Chapter 2 provides in depth background of the genes and proteins that were the focus of 
the study. Chapter 3 covers the applied approach and methods leading to the selection candidate 
genes for investigation. Chapter 4 presents the results and discussion. Chapter 5 summarizes the 
thesis and suggests future work. 
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CHAPTER 2. BACKGROUND 
After the application of the research method, the LAMA4 gene was selected as the main 
gene of interest to study. LAMA4 is a member of the laminin family. Section 2.1 will provide a 
summary of laminin function, structure, and disease associations. Section 2.2 will specifically 
give a description of the LAMA4 gene, the main focus of the study. Section 2.3 will give a brief 
synopsis of the relationship of genetic disorders that present with hearing impairment and 
cardiovascular abnormalities. Section 2.4 will introduce gap junctions and the known functions 
and disease associations. Section 2.5describes the connection of GJB2 to inherited deafness.   
2.1 Laminin Family 
Laminins are a family of extracellular matrix glycoproteins. They are essential for early 
embryonic development and organogenesis and have crucial functions in several tissues including 
muscle, nerve, skin, kidney, lung, and the vasculature (Durbeej 2010). They are the most 
abundant structural non-collagenous glycoprotein present in basement membranes and vital to 
cell recognition, adhesion, migration, and proliferation (Aberdam et. al. 2000).  
Basement membranes are essential to the basic structure and mechanics of cells and 
tissues, forming barriers between cell types, and regulating interactions with other cells (Suzuki 
et. al. 2005). They are thin sheets of extracellular matrix that underlie epithelial and endothelial 
cells and surround muscle cells, Schwann cells, and fat cells. Expression of laminins is tissue 
specific and heavily determined by variations in the expression of the alpha chains (Durbeej 
2010). 
Laminins are composed of three chains: α, β, and γ. Each chain is encoded by its own 
gene: LAMA (α), LAMB (β), or LAMC (γ). To date, five α (named α 1-5), three β (named β 1-3), 
and three γ (named γ 1-3) chains have been identified. These chains assemble to create a cross 
like laminin structure. Thus far 18alpha, beta, and gamma combinations (named laminin-1 to 18) 
have been described (Durbeej 2010). The basic structures of the isoforms are relatively similar 
(Figure 1). An alpha, beta, and gamma chain each make up a unique short arm of the protein. The 
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chains coil together to form a long rigid rod-like structure creating a cruciform structure 
(Iivanainen et. al.1995). N-terminal domains, which are important for laminin network formation 
(Van Agtmael et. al. 2010) are present at the end of each short arm. The C-terminal domain of the 
alpha chain is preceded by the coiled region.  The alpha chain C-terminal domain consists of five 
globular domains known as the laminin G (LG) domain. These globular domains are responsible 
for much of the binding interactions with cellular receptors. Eight laminin isoforms that contain 
α3A, α4, β3, and / or γ2 have a truncated arm due to a shorted N-terminus (Figure 1). 
a)  b)  
Figure 1. Basic structure of a laminin. Blue circles represent the N-terminal domains of each 
chain. White circles are other globular domains. The black circles at the base of the figure 
represent the LG domain. G domains are numbered sequentially (LG1-5) from the base of the 
coiled region. a) General laminin structure. b) Laminin composed with a truncated alpha chain 
(Model adapted from Belkin et. al. 2000, Tunggal et. al. 2000, Van Agtmael et. al. 2010, Durbeej 
2010) 
 
Interactions with laminins are detrimental for basement membrane formation, tissue 
integrity, and biological processes. The LG domains bind to many proteins: heparin and sulfatides 
presumably bind the LG domains of all α chains (Durbeej 2010). The three main cellular 
receptors for laminins are integrins, dystroglycan, and syndecans. (Suzuki et. al. 2005, Durbeej  
2010).  Laminin - integrin binding regulates cell motility, survival, and proliferation. An inability 
of laminins to interact with syndecans compromises basement membrane formation in 
development.  
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Several diseases of the skin, muscle, and nerve are associated with laminins, either 
attributed to a defect in the laminin itself or the cellular receptors. Congenital muscular dystrophy 
is caused by the lack of laminin and alpha-dystroglycan-glycoprotein complex binding due to 
complete or near-complete deficiencies in laminin alpha2 (Suzuki et. al. 2005, McGowan et. al. 
2000). Junctional epidermolysis bullosa (JEB) causes blistering of the skin in response to trauma 
or friction and severe cases can be fatal in first year of life. It is caused by mutations in the three 
genes LAMA3, LAMB3, and LAMC2 that are responsible for encoding the protein chains of 
laminin-5 (McGowan et. al. 2000). Mutations in LAMB2 leading to a deficiency of the laminin 
beta 2 chain contribute to the development of Pierson syndrome which causes ocular anomalies 
contributing to renal failure and loss of vision (VanDeVoorde et. al. 2006, Van Agtmael et. al. 
2010). Relationships of LAMA1 and LAMA4 with rheumatoid arthritis and osteoarthritis have 
been examined (Salmon 1984, Fuerst et. al. 2010). Additionally, the relationship with laminin and 
Alzheimer’s disease is currently under investigation (McGowan et. al. 2000).  
 In summary, the laminin family is not only important to the structure and organization of 
muscle and tissue. Defects in the genes chains can produce debilitating or even fatal functional 
problems.  
2.2 LAMA4 
The human LAMA4 gene encodes the protein laminin alpha 4. It is located on 
cytogenetic band 6q21.  Although countless studies have shed light on the functions of laminin 
alpha 4, its exact function has eluded researchers (Stelzer et. al. 2012). It is predominantly located 
in the endothelial basement membranes of blood vessels. The main expression sites include: 
smooth muscle, fat, peripheral nerve neuromuscular junction, retina, and the central nervous 
system (Durbeej 2010). Research has indicated that LAMA4 is also strongly expressed in the 
adult heart, lung, ovary, small and large intestines, placenta, and liver (Iivanainen et. al. 1995). 
Mouse studies have been conducted to determine expression and function. These studies show it 
is also highly expressed in the aortic endothelium, endocardium and endothelium of blood vessels 
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(Freiser 1997), and cardiac muscle cells (Liu et. al. 1996)  as in human, suggesting outcomes of 
LAMA4 studies with mouse models are relevant to human. 
The structure of laminin alpha 4 is similar to other laminins. It has the closest 
resemblance to the alpha 3 chain however it is also homologous to regions in the alpha 1 and 2 
chains. The short arm is closest in homology to laminin alpha 1 (49.3% sequence identity) 
although it is truncated at the N-terminal domain (Stelzer et. al. 2012, Iivanainen et. al. 1995). 
LAMA2 and LAMA4 also demonstrate homologies in the long arm and LG domain in that they 
are coded by a similar number of exons with few rearrangements. Six of the exons that code for 
these regions are identical in size and exhibit conserved protein motifs (Richards et. al. 1997).  
Integrins α3β1, α6β1, αvβ3 (Suzuki 2005, Gonzales 2002, Lian et. al. 2006) and the 
syndecans act as cellular receptors for laminin alpha 4. Integrin interactions regulate cell motility, 
survival, and proliferation. Interactions with syndecans are involved in cell signaling, adhesion 
and migration in tumors and wound edges (Suzuki 2005).  
Laminin alpha 4 is the alpha chain subunit that combines with beta and gamma chains to 
form laminin isoforms laminin-8(α4, β1, γ1),-9(α4, β2, γ1) and -14(α4, β2, γ3). Research has 
described its involvement in regulating endothelial cell survival through growth and proliferation 
and LAMA4 plays an integral part in proper development of vasculature and structural integrity 
of newly formed capillary basement membranes. Deletion of the alpha 4 protein in mice is not 
lethal but leads to impaired microvessel maturation and cardiomyopathy (DeHahn et. al. 2004, 
Lian et. al. 2006, Thyboll et. al.2001, and Knöll et. al. 2007). It has been shown to compensate in 
the absence or reduced expression of other laminins such as laminin alpha2 (Ringelmann et. al. 
1999). 
To date, no specific human disease has been associated with the laminins containing the 
alpha 4 chain, although mutations in the alpha 4 chain have been characterized in human 
cardiomyopathy (Knöll et. al. 2007). Over-expression of laminin-8 in human dermal 
microvascular endothelial cells has been related to promotion of angiogenesis related functions 
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(Lian et. al. 2006). The function of Laminin-14 expressed in the developing retina could be 
involved in the formation or stabilization of synapses in the CNS, in particular during the 
differentiation of the nervous system in development (Libby et. al. 2000).  
2.3 Hearing Loss and Cardiac Abnormalities 
 Several genetic disorders present with phenotypes that include both hearing impairment 
and cardiovascular abnormalities due to mutual developmental controls (Table 2). More than 100 
genes associated in genetic hearing impairment are also associated to congenital and progressive 
cardiac abnormalities. These genetic disorders present many modes of inheritance including 
matrilineal, de novo dominant mutations, genomic disorders, chromosomal disorders, and familial 
dominant; autosomal-recessive means. The types of genes that are associated with both 
phenotypes are involved in transcription factors, chromatin remodeling, signal transduction 
pathways, ion channels, extracellular matrix proteins, among others (Belmont et. al. 2011).  
 
Table 2. Genomic disorders with both hearing impairment and cardiovascular defects (Belmont 
et. al. 2011).  
 
2.4 Gap Junctions 
 The gap junction gene family encodes Connexin proteins that form permeable channels 
known as gap junctions that connect the cytoplasm of adjacent cells. They regulate cell to cell 
communication by allowing ions and small molecules to pass through. The type of molecules or 
ions that pass through the gap channel facilitates the electrical and biochemical signals sent 
Genomic Disorder Hearing/Ear association Cardiovascular Abnormality
DiGeorge Syndrome & 22q11 Deletion Otitis media, sinorhinitis, hearing loss
Tetralogy of Fallot, interrupted aortic arch type B, 
double outlet right ventricle, perimembranous 
1p36 Deletion Syndrome Deafness
Dialated cardiomyopathy, left ventricular 
noncompaction, ventricular septal defects
6p24 Deletion Syndrome Deafness, auditory hypersensitivity Aortic valve abnormalities
Williams Syndrome Otitis media, conductive hearling loss
Supravalvar aortic stenosis, branch peripheral 
pulmonary arterial stenosis
Long QT syndrome Congenital deafness Heart arrhythmia
Leopard Syndrome Sensorineural deafness Hypertrophic cardiomyopathy
Alstrom Syndrome Sensorineural hearing loss Dialated cardiomyopathy
Osteogenesis Imperfecta Sensorineural hearing loss
When present pathology of left-sided cardiac 
valves, aortic root and ascending aorta.
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between cells and excitable tissues. Distribution of the twenty Connexin isoforms is tissue 
specific, however many cell types express multiple isoforms (Mammano 2000).   
Mutations in gap junctions have been associated with several human pathologies. GJA1 
is integral in the synchronized contraction of the heart and in embryonic development (Stelzer et. 
al. 2012). Mutations in this gene have been associated with severe heart malformations (Dasgupta 
et. al. 2001). Mutations in gap junction genes, GJB3 and GJB2 have also been associated with 
skin disorders such as Erythrokeratodermia variabilis (Gottfried et. al. 2002) and Vohwinkel 
syndrome (Mammano 2000). Charcot–Marie–Tooth disease, linked to mutations inGJA1, causes 
the degeneration of the peripheral nerve which leads to muscle atrophy, sensory disturbance, 
hyporeflexia, and foot deformities (Lin P.et. al. 2010). 
2.5GJB2 
Connexin 26 is encoded by the GJB2 gene. GJB2 is located at cytogenetic band 13q11. It 
is comprised of two exons, one of which contains the coding sequence (Kemperman et. al. 2002). 
Variants in the GJB2 genes are responsible for up to 50% of autosomal recessive nonsyndromic 
deafness in many world populations (Snoeckx et. al. 2005). Specifically, the deletion of a 
gaunonsine nucleotide at position 30 or 35 is the most frequently occurring of the mutations in 
GJB2 responsible for a deaf phenotype to be presented (Kemperman et. al. 2002).   
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CHAPTER 3. MATERIALS AND METHODS 
 
3.1 Approach 
 
A systematic approach was designed to efficiently and effectively search for genetic 
variants that may be causative or contributory to HLHS in the proband. This method begins with 
high throughput sequencing and the subsequent integration of various bioinformatics tools to 
analyze and investigate the relationship of these finding to the syndrome in the proband (Figure 
2). 
 
Figure 2:Novel variant detection and disease association approach. 
 
3.2 Justification of Methodology 
Although 454 pyrosequencing is a very reliable method, errors do occur. The dominant 
error type for the 454 platform is insertion-deletion, usually due to consecutive instances of the 
same base. Another error type that is possible is the miscalling of a nucleotide 
(Shendure&Ji2008). Sanger sequencing is a reliable method to validate pyrosequencing results 
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and typically used as the secondary analysis method to verify variant identification. Primers can 
easily be designed with publically available software from NCBI to flank the specific sequence 
variants. Turnaround time is also rather quick and sample processing of small sample sets is 
relatively inexpensive. 
The mode of inheritance of HLHS is proposed to be autosomal recessive (Hinton et. al. 
2007). Based on the rate of occurrence it is likely variants found in more than 1% of the general 
population are not the cause of this syndrome, therefore, the novelty of the variant needs to be 
verified before further investigation. Mutation prediction tools such as SIFT and PolyPhen are 
publically available and include web-interfaces for small queries. These tools not only provide 
that a specific variant is novel but also calculates the likelihood that the change from the reference 
sequence is non-synonymous, damaging, or tolerated. The algorithms use structural and sequence 
information to predict the impact of substitution on the structure and function of a protein. 
Determining the conservation of the amino acid provides a measure its functional importance at 
that position in the protein. Highly conserved amino acids are inferred as being more important to 
the function of the protein. 
Pathway analysis can provide insight and potential avenues to explore and aid in the 
identification of genes and proteins associated with the etiology of a disease. Pathway-based 
analysis can mark the genes associated with a disease or phenotype and separates them from false 
positive hits and can also be useful in identifying biological pathways affected by the genes (Wu 
2010).  Pathway analysis has been implemented in many areas including cancer research (Wu 
2010. Xiao et. al. 2011) and successfully identified significant group effects on several gene-gene 
pathway interactions relevant to IBD. Ingenuity Pathway Analysis (IPA, Ingenuity® Systems) is 
a commercially available tool and GeneMANIA (Warde-Farley et. al.2010) is free web-based 
software. Both tools were used as confirmation of results. GeneMANIA was also implemented as 
a quick scan for interactions.  
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Homology modeling is also an effective method used to infer the effect of a single variant 
in a gene. Mossé et. al. (2008) conducted a linkage study of twenty families with varying degrees 
of confidence of inheritance of neuroblastoma predisposition genes. Probands were sequenced for 
novel variants found in the anaplastic lymphoma kinase (ALK) gene. Homology modeling of the 
wild type and mutant forms of the gene made it apparent that the structure was dramatically 
altered due to the location of the mutations in an activation segment and in a glycine looping 
region.  This data along with other experimental data in the study made it possible for researchers 
to determine that ALK is a critical neuroblastoma oncogene.  
Pedigree studies have been an invaluable tool for the identification of causative and 
contributive genes in genetic disease. Perhaps the most famous pedigree is one that illustrates the 
inheritance of hemophilia in the family of Queen Victoria of England. Due to the well-mapped 
pedigree, researchers have recently identified a mutation in the F9 gene on the X chromosome as 
the causative gene responsible for hemophilia B in the Romanov branch of the royal family 
(Rogaev et. al. 2009). Familial studies have also been integral to the discovery of the 
Huntington’s disease gene HTT (Chial 2008), mutations causative to development of cystic 
fibrosis (Danes et. al. 1977), and sickle cell anemia (Frenette et. al.2007). These types of studies 
are useful in determining whether there is a genetic relationship involved in a disease even if it 
does not tease out the causative genes. Hinton et. al. (2007) used family pedigree analysis to 
determine hypoplastic left heart syndrome is heritable. In a study of 38 families affected by this 
syndrome pedigree analysis supported that HLHS in almost entirely caused by genetic effects. 
 Extended pedigrees increase statistical power for gene discovery and represent a more 
homogeneous and limited set of causative genes and pathways especially in complex traits such 
as heart disease. Such complex traits tend to be common and cluster in families but do not always 
follow clean Mendelian segregation patterns. They may be caused by many genes and affected by 
multiple pathways in which multiple defects or mutations lead to the phenotypic variation. 
Familial studies are advantageous in revealing underlying causes as they benefit from the shared 
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genetic background and similar environmental exposures in comparison to studies with non-
related cohorts (Borecki 2008).  
3.3 Exome Capture 
 
21µg of input DNA was used with the NimbleGen Sequence Capture Human Exome 
2.1M array (Roche NimbleGen, Madison, WI).  The Human Exome Array targets ~180,000 
human protein coding exons and ~700 miRNA exons using 2.1 million long oligonucleotide 
probes (>60mer) on a single microarray. The captured fragments were sequenced with Roche 
protocol for Titanium chemistry on the 454 GS FLX instrument (Roche 454, Branford, CT). The 
sequence reads were aligned to human genome reference sequence NCBI 36.3 and variants were 
identified with Roche 454 gsMapper software.  
Variants were annotated with a clinical in-house variant analysis platform, Carpe Novo, 
to determine candidate mutations to investigate (Worthey et. al.2011). Carpe Novo incorporates 
four stages of analysis. Primary analysis includes sequencing analysis. Secondary analysis is the 
sequence alignment, variant calling, and the consideration of data from the sequencing run such 
as depth of coverage and number of reads. Tertiary analysis consists of the annotation of variants. 
Quaternary analysis involves running queries on the annotated data to further narrow the potential 
candidate list (Worthey et. al.2011, Davies 2011).    
3.4 Confirmation of Exome Sequencing Results.  
 Confirmation of the exome sequencing was a two part process. The first step in the 
process was to design primers that would detect the variant found in exome sequencing. This step 
involved submitting the nucleotide coordinates to validate the variant in build 36.3 with the NCBI 
Map Viewer tool found at the following web address: 
http://www.ncbi.nlm.nih.gov/projects/mapview/map_search.cgi?taxid=9606&build=previous 
(Wolfsburg 2011). The second step was to verify the variants retained their novel and damaging 
status from the initial date of analysis to the date of primer design.  
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3.4.1 Primer Design 
NCBI Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) was used to 
generate forward and reverse primers flanking each variant. To narrow in on the variant 
nucleotide positions plus and minus 500 base pairs were entered in the Range Section. If initial 
testing resulted in several bands, this length allowed for easier nested primer design. Primer Pair 
specificity Checking parameters were as follows: 
• Specificity Check: enable search for primer pairs specific to the intended PCR product = 
enabled.  
• Organism: 9609 (Human) 
• Database: Genome (reference assembly from selected organisms)  
• Primer specificity stringency: 2 total mismatches to unintended targets, including at least 
2 mismatches within the last 5 base pairs at the 3’ end. Ignore targets that have 7 or more 
mismatches to the primer (default) 
 
Primer selection criteria required 2 mismatches to be present within 5 bases of the 3’ end 
of the reverse primer. The more mismatches present for other products in the primer pair, the 
more specific the primer is expected to be for the intended product.  As several primers may 
cover the area of interest, primers with the greatest number of mismatches with unintended 
targets were selected. These mismatches on the end are to further ensure specific to the intended 
target sequence. Single and nested primer pairs were designed to confirm the variants found in the 
exome sequencing (Table 3). 
PCRs were conducted for each variant primer set. 5ng of proband DNA sample was 
denatured at 94°C for 15 minutes and amplified for 40 cycles, each consisting of 30 seconds at 
95°C, 30 seconds at 53°C, and 45 seconds at 72°C, followed by a 10-minute extension at 72°C. 
4µl of PCR product was visualized on a 2% agarose gel stained with ethidium bromide. PCR 
product was cleaned by and ExoSAP-IT reaction and sent to Retrogen, Inc. (San Diego, CA) for 
sequencing reactions. Sequencing results were analyzed with Sequencher DNA analysis software.  
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Table 3.Primer pairs for PCR confirmation of variants. 
 
3.4.2. Confirmation of Novel Status 
Amino acid conservation among species was verified with mouse, rat, chick, and 
zebrafish.  UniProtKB identifiers for each species were retrieved from the UniProt Consortium 
Protein Knowledgebase (Jain 2009, Magrane 2011). BLAST alignment with the clustalo 
algorithm was conducted. 
Gene Size (bp) Sequence
Taldo1 forward GTGGGGAGCGGCCATTCGTC
Taldo1 reverse GTGGGACGCACACGTGGGAG
KCNJ12 forward TACGGGCTGCGCTGTGTGAC
KCNJ12 reverse GGGGCGTAGAGGGCACCTCA
ARSD forward TGGGTTGCTCCGTGACGTCA
ARSD reverse GCGGGGATCACTGCCACCAC
GOLGB1 forward CCACCCCTACCTGTGCAGGTTGT
GOLGB1 reverse ACTGATGGGAGCAAGAAAAACCAGC
OR7C1 forward AGGCCACCAGACTTGTCGCC
OR7C1 reverse TCGAGCAGGGAACCCATGACACT
CDC27 forward AGTACCAGCACCATCAATACGACTTTG
CDC27 reverse GTTCCCTGCAGCACACCAGGC
Taldo1 forward TCATAGTCAGGTGAACTGAG      
Taldo1 reverse TCACCCCCATTGCCTTTCTT
KCNJ12 forward TAACCTGCGCAAGAGCCACA
KCNJ12 reverse AAAGTCGTCCGTCTCCAGGT
ARSD forward AACTGGGTGTAACCCCAGAG
ARSD reverse GAACCACGGATTTGACTATT
GOLGB AGGTTGTTCTGCCTGTGCCT
GOLGB TGTAGAACTCTTGTCATGCTGA
OR7C1 ACCTAGAAGATGGTGTGGCT
OR7C1 TTGTGCTTTCTCCCAGCTGA
CDC27 AATGTCTAGGATTGACTCTG
CDC27 CAATATCATGTTCCCGTTGCA
MAGEC1 forward TCCCCAGTCTCTTCTCCAGATTCCT
MAGEC1 reverse CCTCCCCCTGAGGAGGGCTC
OR4C3 - 1 forward ACACCTGCAGCATGCCTAGAACA
OR4C3 - 1 reverse TGTTGTCTCCTGCACCTAGCACT
OR4C3 - 2 forward ACACCTGCAGCATGCCTAGAAC
OR4C3 - 2 reverse CATGTTGTCTCCTGCACCTAGCAC
OR4C3 - 3 forward ACACCTGCAGCATGCCTAGAACA
OR4C3 - 3 reverse TGTTGTCTCCTGCACCTAGCACT
AKAP13 forward GGGATACCCAGGAACGTGCGGA
AKAP13 reverse CTGGGATTGCTGGAGGGGCG
CD2BP2 forward CCCTCCAAGAGGGCTTGGGC
CD2BP2 reverse ACCCTGTGGCTGGGTCAGGG
LAMA4 forward TTCCAGCCTCCCTGTGGCCA
LAMA4 reverse AGCAAGTTGTTTAGTTCACCCAAACCA
OR1J2 forward ACCAGAGCAGCGTGTCCGAGT
OR1J2 reverse CCCTCAGGATGGTGGCCCCA
OR52N2 forward CCTGCCCTATTGCCGGGGGA
OR52N2 reverse TGGGTTCATGGTAGGAGGCAGTAGC
782
630
332
271
322
260
163
232
120
123
121
168
924
668
375
719
605
608
606
476
618
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The UCSC liftOver tool (Haussler 2006) enables researchers to translate nucleotide 
positions aligned to previous builds in the NCBI reference genome to other or more current 
releases. A BED file with the minimum of the following three fields: chromosome (chrom), 
starting position of the chromosome (chromStart), and the ending position of the chromosome 
(chromEnd) is required for submission to the tool (Hinrichs et. al. 2006). The start and stop 
position of the chromosome(s) being queried are returned. The position of the variant of interest 
is subtracted from the end position of the chromosome in the original assembly in order to 
translate the updated coordinates in the queried assembly.   
The NCBI37/hg19 nucleotide coordinate was used as search criteria to verify no SNP 
data is associated with the variant. A SNP identification number is necessary for determining if a 
SNP exists within dbSNP. Since the variants examined in this study were novel, there was no 
SNP identification value. The coordinates of the variant and sequence were very useful in 
confirming with NCBI whether a SNP had been identified with this variant and either missed by 
the initial carpe novo analysis or updated since that original analysis.   
SIFT analysis (Ng & Henikoff 2003) was repeated with the updated nucleotide 
coordinates to ensure the novel and damaging status remained current. The chromosome number, 
variant position, orientation and alleles were entered into the web based submission form. OMIM 
Disease and Allele Frequencies (All HapMap Populations) output options were selected (Ng & 
Henikoff 2003).  
Polymorphism Phenotyping (PolyPhen) analysis was repeated using the amino acid 
position and substitution. This pipeline calculates the potential impact of an amino acid 
substitution on the structure and function of a protein. A numerical score ranging from 0.00-1.00 
is returned from the input queries. The higher the score, the more likely the amino acid change is 
damaging to the structure and function of the queried protein (Adzhubei et. al. 2010).  
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3.5 Protein Model Development 
Homology models of wild type and mutated genes were generated with MODELLER 
v9.10 (Šali 1993) and PyMOL v0.99 software (The PyMOL Molecular Graphics System). Genes 
with resolved crystal structures were aligned with the sequences of the mutated genes with 
BLAST. The most homologous crystal structure found in Protein Data Bank (pdb - Bernstein 
1977) and the Protein Families Database (Pfam - Punta et. al.2012) was used as the backbone for 
the mutated gene to be threaded upon. The .pdb file was loaded into PyMOL with the PDB Plug-
in Loader Service. All hydrogen, water, and sugar molecules were deleted as they are not 
necessary for the MODELLER software. Blastp alignment was conducted to verify the sequence 
segment to utilize for the wild type and mutated models. 
The MODELLER align2d.py script (Altschul 1990) was used to generate the final 
alignments to the known structures. The alignment generated by this step is input to the Model-
single.py script for calculation of the 3D models in .pdb format. These models are viewed in the 
PyMOL software and analyzed. The model that retained the most structural homologies within 
the model set was selected as the final representative model.  
3.6 Pathway Analysis 
Two methods of pathway analysis were conducted with the IPA tool (Ingenuity® 
Systems). The first method generated a general sense of the gene neighborhoods to explore if any 
of the candidate genes are closely related in a pathway.  Each gene was queried under the Genes 
and Chemicals search. The interaction network option was selected to view the figure 
representing the relations and the build tool was used to grow pathways from the query gene. 
Individual queries were run based on indirect/direct interactions and relationship types. Examples 
of interactions used as ‘grow’ criteria were: direct, protein-protein interaction, indirect protein-
protein interaction, direct regulation of binding, etcetera. All relationship query types were 
examined in order to get a full picture of all possible relationships.  
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The interaction neighborhoods were exported to a .csv file which was then modified to 
include the gene queried, direct or indirect interaction, and relationship type. The .csv files were 
merged with a python script. The combined file was used to determine if any of the neighborhood 
genes overlapped with other gene queries.  The overlapping genes were then compared to the 
exome date to determine if variants were found in these genes but then not considered for 
evaluation due to a non-damaging or non-novel status. An additional list of genes reported to be 
involved with CHD, HLHS, and Turner’s syndrome were also examined in this manner (Table 4). 
 
Table 4. Genes with cardiac or Turner’s syndrome associations. These genes were used in IPA 
pathway analysis. See bibliography for references. 
 
The second method of IPA network analysis was to generate a graphical representation of 
the molecular relationships between the candidate genes and HLHS. Cardiac disease and 
functions such as: Hypertrophy of cardiac muscle, HLHS, hypertrophy of heart, congestive heart 
failure, heart disease, coronary disease, and left ventricular dysfunction were overlaid to visually 
determine if any the candidate genes have a cardiac related function or were closely related to 
genes associated with HLHS.  
Additional pathway analysis was conducted with GeneMANIA (Warde-Farley et. 
al.2010) to examine potential interactions of candidate genes in the study, known cardiac genes, 
and gap junction genes. GeneMANIA utilizes publicly available genomic and proteomic data sets 
such as GEO, BioGRID, Pathway Commons, and I2D for prediction of functional relationships or 
Gene Association Reference
ATRX Turner's syndrome Tomita-Mitchell 2012
BCOR Turner's syndrome Tomita-Mitchell 2012
EHMT1 CHD Kleefstra 2006
ERBB4 CHD McBride 2011
FKBP6 Turner's syndrome Tomita-Mitchell 2012
FLNA Turner's syndrome Tomita-Mitchell 2012
FOXC1 HLHS Grossfeld 2009
GATA4 CHD Draus 2009, Rajagopal 2007, Tomita-Mitchell 2007, Tomita-Mitchell 2012
GJA1 HLHS Grossfeld 2007, Grossfeld 2009, Hinton 2009
GPC3 Turner's syndrome Tomita-Mitchell 2012
HAND1 HLHS Grossfeld 2009, Reamon-Buettner 2008
MID1 Turner's syndrome Tomita-Mitchell 2012
MYH11 CHD Zhu 2006
NKX2.5 HLHS Elliott 2003, Grossfield 2007, Grossfeld 2009, McBride 2008, Stallmeyer 2010
NOTCH1 HLHS Grossfeld 2009, Grossfeld 2007, McBride 2008
SOX7 CHD Wat 2009
ZIC3 Turner's syndrome Tomita-Mitchell 2012
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shared properties of genes. It supports data for Arabidopsis thaliana, Caenorhabditis elegans, 
Drosophila melanogaster, Mus musculus, Homo sapiens, and Saccharomyces cerevisiae (Warde-
Farley et. al. 2010). GeneMANIA suggests annotations for genes based on Gene Ontology term 
enrichment of highly interacting genes with the query gene and is a gene recommendation system 
(The Gene Ontology Consortium 2000). The queries were weighted according to the Gene 
Ontology (GO) biological function weighting method. This weight reflects the data source 
relevance for predicting the function of interest (Warde-Farley et. al. 2010). GeneMANIA output 
was used in conjunction with IPA analysis to verify and generate hypothesis of gene 
relationships. 
3.7 Family Pedigree Analysis 
To examine the potential relationship of the CHD and deaf phenotype in the family, 
primers designed and published by Snoeckx et. al. for detecting the connexin26 deletion: Cx26F 
(5’-TCTTTTCCAGAGCAAACCGC-3’) /Cx26R (5’- GGGCAATGCGTTAAACTGGC-3’) 
were used in Sanger sequencing reactions with all available family DNA samples. DNA sample 
was denatured at 94°C for 15 minutes and amplified for 40 cycles, each consisting of 30 seconds 
at 95°C, 30 seconds at 63°C, and 45 seconds at 72°C, followed by a 10-minute extension at 72°C. 
4µl of PCR product was visualized on a 2% agarose gel stained with ethidium bromide. PCR 
product was cleaned by and ExoSAP-IT reaction and sent to Retrogen, Inc. (San Diego, CA) for 
sequencing reactions. Sequencing results were analysis with Sequencher DNA analysis software.  
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CHAPTER 4. RESULTS AND DISCUSSION 
4.1 Exome Sequencing and Sanger Sequencing Analysis 
Exome sequencing resulted in an average depth of 36X coverage. Enrichment was 
approximately 75-fold.  60% of reads mapped to targeted regions and more than 99% of the 
intended targeted region was covered.  Carpe novo data analysis identified more than 13,000 
coding differences compared to the human genome reference (NCBI36/hg18) were found. More 
than 1400 of these coding differences (variants) were novel (Worthey et. al.2011). 
PolyPhen (Adzhubei et. al 2010) and SIFT (Ng &Henikoff 2003) analyses were then 
utilized to further prioritize variants. The more conservative PolyPhen analysis was conducted 
first due to the ability to automate the process in house. Non-synonymous sequence variants in 
approximately 140 genes were predicted to be “damaging”. This data set was then entered into 
SIFT (www.http://sift.jcvi.org/) and further reduced to 13 genes when sorted by status according 
to SIFT. The variant positions and nucleotide results were confirmed against NCBI map viewer 
human build 36.3 before confirmation with Sanger sequencing. 
PCR Primer sets for variants found in genes TALDO1, KCNJ12, ARSD, LAMA4, and 
AKAP13 generated clean results when visualized on the 2% agarose gel, reducing the number of 
variants of interest to five (Figure 3). The DNA samples of immediate family members:  father, 
mother, unaffected sibling, and fetal tissue were screened. Sanger sequencing results were aligned 
and analyzed with Sequencher DNA Sequencing Software, further reducing the number of 
variants to potentially investigate (Table 5). 
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Figure 3. Gel Electrophoresis results of TALDO1, KCNJ12, ARSD, LAMA4, and AKAP13. 
These products were sent for sequencing confirmation. Lane 1: 100bp DNA Ladder (Invitrogen) 
Lanes 2-5: Negative controls (TALDO1, KCNJ12, ARSD, AKAP13, LAMA4). Lanes6-10: 
Positive Negative controls (TALDO1, KCNJ12, ARSD, AKAP13, LAMA4). Lanes 11-15: 
TALDO1. Lanes16-20: KCNJ12.  Lanes21-24: ARSD. 100bp DNA Ladder 
(Invitrogen).Lanes26-29:AKAP13. Lanes30-33: LAMA4.100bp DNA Ladder (Invitrogen) 
Sample order is: Proband, Father, Mother, Unaffected Sibling, Fetal tissue. 
 
 
Table 5.Sanger sequencing confirmation. Nucleotides listed in the ‘Expected’ column are 
expected according to the NCBI36/hg18 assembly. Nucleotides listed in the ‘454’ column 
indicate nucleotide variants found in the exome sequencing reaction. Primer sets for variants 
found in genes ARSD, Taldo1, and KCNJ12 did not confirm the variants found in the exome 
sequencing reaction. 
 
The AKAP13 PCR reaction confirmed the exome sequencing finding of a nucleic acid 
change from cytosine to thymine at position 83,924,813 (NCBI36/hg18 assembly). The initial 
decision was to not pursue the variant in this gene as the mode of inheritance is not 
straightforward since all family members except the mother carry the variant. A point of interest 
for this variant is that there is a second peak at this position in all members that carry the 
mutation. A cytosine peak is present that is approximately 10% the height of the thymine peak 
(Figure 4). 
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Figure 4. Chromatograms of AKAP13 and LAMA4 Sanger sequencing results: a.AKAP13 
cytosine present in DNA sequence of the mother. b. Thymine variant found in other family 
members – note presence of slight cytosine peak. c. LAMA4 cytosine present in father and 
unaffected sibling. d. Heterozygous variant in proband, mother, and fetus.  
 
The list of variants of interest ultimately was reduced to the variant found in LAMA4 at 
position 112570046(NCBI36/hg18 assembly). The chromatograms of the proband, mother, and 
fetus indicate they all are heterozygous for the LAMA4 variant (guanine) and expected nucleotide 
(cytosine). The father and unaffected sibling both have a single cytosine peak at this position 
(Figure 2c, 2d).  PCR sequence analysis of extended family members including a non-HLHS 
sibling, maternal grandparents, maternal half great uncle and aunt, maternal aunt, & maternal 
cousin showed that the non-HLHS sibling and maternal grandmother are also heterozygous for 
the LAMA4 variant. 
4.2 Variant Pathway Analysis 
The 13 genes of interest were analyzed through the use of IPA (Ingenuity® Systems, Inc. 
Redwood City, CA). Output files were combined and compared to find genes that overlapped 
among the twelve candidate’s gene neighborhoods. Some neighborhood overlaps did occur, 
however further pathway analysis did not indicate a clear relationship to cardiac defects (Table 
6). Variants in IL2 (interleukin 2 - cytokine) and SKIL (ski-like oncogene) were found in the 
exome sequencing results but were not novel or predicted as damaging. GeneMANIA queries of 
these genes, with LAMA4 did not result in physical or pathway relationships. 
FOXM1 (cell proliferation), TNF (tumor necrosis factor), and ZHX1 (zinc finger and 
homeobox) were shared in LAMA4 neighborhoods but no mutations in these genes were found in 
the exome sequencing.  These genes do not have implied cardiac functions, however to 
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potentially sift out potential relationships, a GeneMANIA query was run to screen for interactions 
with HLHS genes GJA1 and PDE5A to potentially view pathway connections that could be 
related to HLHS and no significant relationships were returned.   
 
Table 6. Overlapping genes found in query neighborhoods. IL2 and SKIL Genes in column one 
are also found to have non-novel mutations in the exome sequencing results. Key: PP: protein-
protein binding, PD: protein-DNA binding, RB: regulation of biding, MB: Group/complex 
membership, LO: localization, E: expression (includes metabolism/synthesis for chemicals). D: 
direct interaction, I: indirect interaction. 
 
 The outputs from the variant neighborhood analysis were also compared to the gene list 
in Table 3. Overlapping genes were compared to the exome sequencing data to determine if 
variants were found but not considered for evaluation due to a non-damaging or non-novel status. 
The purpose of this comparison is to ascertain if the novel mutation alone is not responsible for 
the development of HLHS but coupled with other mutations (possibly not novel) HLHS could 
develop. PRKCA was found in these results, the 13 genes of interest neighborhood output, and 
454 exome results (Table 7). 
  
Symbol Family From Neighborhood Relationship Type Interaction
FOXM1 transcription regulator CDC27 PP D
FOXM1 transcription regulator LAMA4 PD D
FYN kinase CD2BP2 RB I
FYN kinase CDC27 PP D
HNF4A transcription regulator AKAP13 MB D
HNF4A transcription regulator KCNJ12 PD D
IL2 cytokine AKAP13 LO I
IL2 cytokine CD2BP2 LO I
SKIL transcription regulator CDC27 PP D
SKIL transcription regulator GOLGB1 PP D
TNF cytokine LAMA4 E I
TNF cytokine TALDO1 E I
ZHX1 transcription regulator LAMA4 PP D
ZHX1 transcription regulator TALDO1 PP D
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Output 
Gene 
Variants of 
Interest 
Associated 
Genes 
Exome 
variant 
CDKN1A CDC27 NOTCH1 no 
CTNNB1 AKAP13 GJA1 no 
ESR1 AKAP13 ERBB4 no 
IL5 AKAP13 GATA4 no 
ITGB1 LAMA4 FLNA no 
ITGB3 LAMA4 FLNA no 
PRKCA AKAP13 GJA1 YES 
SMAD3 CDC27 NOTCH1 no 
SRF AKAP13 MYH11 no 
TP53 LAMA4 NOTCH1 no 
Table 7. Common genes in exome data and additional gene list. PRKCA was found in both the 
variant gene list and the additional gene list neighborhoods (Table 4). PRKCA was found to have 
a variant in the exome sequencing data. The PRKCA variant found in the exome sequencing 
results in the nonsynonymous coding change of amino acid valine (nonpolar neutral) to isoleucine 
(nonpolar neutral). The SIFT score is 1 deeming the change tolerated. The mutation is identified 
with dbSNP ID rs6504459 and therefore not novel. 
 
PRKCA is a kinase that has been reported to play roles in many different cellular 
processes, such as cell adhesion, cell transformation, cell cycle checkpoint, and cell volume 
control (Stelzer et. al. 2012). In epithelial studies it has been indicated that the failure to down-
regulate PRKCA increases leakiness of tight junctions (Mullin et. al. 2000). It also promotes 
angiogenic activity of human endothelial cells (Xu et. al. 2008) implying a potential relationship 
with GJA1 and LAMA4. It also has been studied in regards to its role in cardiac function. 
PRKCA controls myocardial contractility in mice and rats with cardiac disease. Knockout studies 
have shown null PRKCA mice have enhanced cardiac contractility and reduced susceptibility to 
heart failure whereas over-expression showed decreased cardiac contractility, ventricular dilation, 
and secondary hypertrophy (Ladage et. al. 2011)  
The GeneMANIA query of PRKCA, known HLHS gene GJA1, and candidate genes 
LAMA4, and AKAP13 with Gene Ontology (GO) biological function based weighting returned 
one direct genetic interaction between LAMA4 and AKAP13 (Figure 5). This interaction returned 
the lowest weight of all interactions between query genes (4.55E-04) and was supported by one 
publication (Lin A. et. al. 2010). A similar pathway query did not show connectivity among the 
genes except in the case of LAMA4 and PRKCA, and again was the weakest interaction in the 
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network query (0.005128629). This pathway relationship was only supported by one publication. 
Physical Interactions accounted for 82.62% of the network interactions in this query meaning any 
interaction with these genes is more likely to be physical rather than pathway or genetic. 
Although the weights of the predicted interactions among the query genes were not exceptionally 
high, interactions between PRKCA and AKAP13 and PRKCA and GJA1 were supported by iRef-
BIND, Bio-Grid-small scale studies, IREF-OPHID, and iRef -small scale studies. These genes 
may be found to indirectly work together in the formation of HLHS when more data is published.  
 
Figure 5. Genetic, pathway, and physical interactions. LAMA4, GJA1, PRKCA, and AKAP13(as 
predicted by GeneMANIA)share physical, pathway, and genetic interactions. 
 
The second method of IPA network analysis generated a graphical representation of the 
molecular relationships between the twelve genes of interest and HLHS or cardiac disease or 
function. The input for this representation were the original thirteen genes, GJA1, and PDE5A. 
GJA1 and PDE5A were included as they were returned from an IPA Functions and Diseases 
query of HLHS. Cardiac associations shown in Figure 6 were overlaid to visually determine if 
any the genes have a cardiac related function. This visual representation indicates LAMA4 and 
AKAP13 are involved in several cardiac related diseases functions and therefore could potentially 
be involved in the development of HLHS in this family. 
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Figure 6.Variant and Cardiac Relationships. Disease Molecules and disease are represented as 
nodes and the biological relationship between two nodes is represented as an edge (line). All 
edges are supported by at least one reference from the literature, from a textbook, or from 
canonical information stored in the Ingenuity Knowledge Base. Molecule nodes are displayed 
using various shapes that represent the functional class of the gene product. Function / disease 
nodes are oval (© 2000-2010 Ingenuity Systems). 
 
 
4.3. Novel Variant Selection 
Pathway analysis and Sanger sequencing confirmation of the first five family members 
that provided DNA samples indicated that LAMA4 was a potential candidate to play a role in the 
development in HLHS. Literature searches supported that there may be involvement of LAMA4 
with HLHS due to the integral role of LAMA4 in cell communication, scaffolding, development, 
and the circulatory system (refer to Chapter 2.2). 
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4.3.1 Justification 
Several hypotheses regarding the development of HLHS suggest the mutation found in 
the LAMA4 gene may be causative or contributive to the development of CHD in this family.  
One accepted hypothesis, supported by research in embryonic chick, states that HLHS develops 
late in embryogenesis as a result of embryonic alterations in blood flow, such as premature 
narrowing of the foramen ovale and aortic stenosis (Hinton et. al. 2007, Dasgupta et. al. 2001). 
Given the alpha-4 subunit is involved in angiogenesis and endothelial branching morphogenesis 
(a component of blood vessel development) it is feasible to consider the likelihood that LAMA4 
plays a role in the development in HLHS.  This is further supported by a second hypothesis that 
suggests that the extracellular matrix protein signaling molecules could serve as HLHS causing 
genes (Hinton et. al. 2007).  
LAMA4 is located in close proximity to another region also related to cardiac defects on 
chromosome 6. A family-based genome-wide linkage analysis performed on families with an 
HLHS or bicuspid aortic valve (BAV) proband linked HLHS to chromosome 6q23 (Hinton et. al. 
2009). The 6q22-23 region is also linked to familial dilated cardiomyopathy and conduction 
disease (Messina et. al. 1997). Char syndrome is caused by mutations in TFAP2B located in 
region 6p12-21.1. Cardiovascular abnormalities such as patent ductus arteriosus (the connection 
between the aorta and the pulmonary artery does not close after birth) are commonly present in 
patients with this syndrome (Vaughan & Basson 2000). Perhaps the proximity of LAMA4 to 
these regions can be considered as a risk factor.     
Several studies have linked LAMA4 to cardiovascular development, function, and 
dysfunction. Knöll et. al. (2007) discovered two novel amino acid mutations in the LAMA4 gene 
that lead to a loss of integrin binding capacity. They discovered that a function of integrin –linked 
kinases is to maintain morphology of the ventricle during embryonic development and to 
maintain cardiomyocyte shape. This function is dependent on the LAMA4 gene suggesting that 
mutations in this gene causing conformational changes will interfere with the interaction of 
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endothelial cell and cardiomyocytes with the extracellular matrix.  This interference may cause 
cardiomyopathy and ultimately lead to death (Knöll et. al.2007) 
Studies with model organisms such as chick and mouse have been conducted to better 
understand human cardiac development. Nath et. al. (2009) determined that endothelial cell 
differentiation is a critical factor in heart development. These studies have also indicated that 
there are overlapping developmental pathways in vasculature and heart.  Additional studies with 
laminin alpha-4 deficient mice have demonstrated an ischemic cardiac phenotype caused by a 
mutation in the laminin alpha 4 chain. Although mice survive development, 20% of the null mice 
died in the perinatal stage. Surviving litter mates did not express a notable phenotype but had 
increased frequency of sudden death.  The null laminin alpha-4 mice possessed altered 
extracellular matrix structures that created an inefficient flow of blood to the heart due to cardiac 
hypertrophy and cardiac dysfunction (Wang et. al. 2009). Additional studies show null laminin 
alpha-4 mice leads to impaired blood vessel maturation. Capillary basement membranes are weak 
causing fatal hemorrhaging in 50% of the null laminin apha-4 mice (Thyboll et. al. 2001).  This 
discovery could be pertinent if HLHS is acquired due to restriction of left heart blood flow in 
embryogenesis as suggested by Dasgupta et. al. (2001). 
4.3.2. Supporting Pathway Analysis 
Pathway analysis with IPA (Ingenuity® Systems) supported the pursuit of LAMA4 in 
regards to HLHS. Figure 6 is a graphical representation of the thirteen genes of interest and their 
relationships to cardiovascular disease and system development and function. Each relationship 
has a p-value calculated using the right-tailed Fisher Exact Test (Table 8).  The p-value is a 
measure of the likelihood that the association between the molecules and a given function is due 
to random chance. The smaller the p-value, the less likely the association is random, and the more 
significant the association. In general p-values less than 0.05 indicate a statistically significant, 
non-random association (Ingenuity® Systems, www.ingenuity.com). The calculated p-values for 
the data set of the twelve genes of interest including GJA1 and PDE5A statistically support the 
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importance of the role of LAMA4 in the cardiovascular system. It was not indicated to have a 
relationship with HLHS; however, the other relationships within the cardiovascular system may 
lead to causal or contributory factors.  
 
Table 8. Calculated p-values of figure 6 data. Only statistically significant p>0.05 values are 
included. 
 
4.3.3 Verification of LAMA4 Gene Variant 
To verify amino acid conservation among species, protein identification for LAMA4 in 
mouse, rat, chick, and zebrafish was retrieved from the UniProt Consortium Protein 
Knowledgebase (Jain 2009, Magrane 2011). BLAST alignment with the clustalo algorithm was 
conducted with the UniProtKB identifiers for each species: Q16363 (Human), P97927 (Mouse), 
Q5SNU9 (Zebrafish), F1NSZ5 (Chick), and F1RZM4 (Pig). The alignment confirmed 
© 2000-2012 Ingenuity Systems, Inc. All rights reserved.
Category Function Function Annotation p-value Molecules # Molecules
Cardiovascular Disease hypoplastic left heart syndrome hypoplastic left heart syndrome 1.66E-06 GJA1, PDE5A 2
Cardiovascular System Development and Function morphology morphology of blood vessel 8.92E-05 GJA1, LAMA4 2
Cardiovascular Disease hypertrophy hypertrophy of cardiac muscle 1.36E-04 AKAP13, PDE5A 2
Cardiac Hypertrophy hypertrophy hypertrophy of cardiac muscle 1.36E-04 AKAP13, PDE5A 2
Cardiovascular System Development and Function morphology morphology of coronary artery 5.46E-04 GJA1 1
Cardiovascular System Development and Function coupling coupling of proepicardial cells 5.46E-04 GJA1 1
Cardiovascular System Development and Function migration migration of proepicardial cells 5.46E-04 GJA1 1
Cardiovascular System Development and Function proliferation proliferation of proepicardial cells 5.46E-04 GJA1 1
Cardiac Proliferation proliferation proliferation of proepicardial cells 5.46E-04 GJA1 1
Organ Development development development of primary ovarian follicle 5.46E-04 GJA1 1
Cardiovascular Disease atherosclerosis atherosclerosis of abdominal aorta 1.09E-03 GJA1 1
Cardiovascular Disease endocardial cushion defect endocardial cushion defect 1.09E-03 GJA1 1
Cardiovascular System Development and Function communication communication of endothelial cell lines 1.09E-03 GJA1 1
Organ Development development development of secondary ovarian follicle 1.09E-03 GJA1 1
Cardiovascular System Development and Function contraction contraction of heart 1.49E-03 GJA1, KCNJ12 2
Cardiovascular Disease angina pectoris angina pectoris 1.69E-03 KCNJ12, PDE5A 2
Cardiovascular System Development and Function branching branching of endothelial cell lines 2.18E-03 LAMA4 1
Cardiovascular Disease congestive heart failure congestive heart failure 3.03E-03 KCNJ12, PDE5A 2
Cardiovascular Disease cerebral vasospasm cerebral vasospasm 3.81E-03 PDE5A 1
Cardiac Degeneration degeneration degeneration of cardiomyocytes 4.90E-03 LAMA4 1
Cardiovascular Disease heart disease heart disease 6.17E-03 AKAP13, GJA1, KCNJ12, LAMA4, PDE5A 5
Cardiovascular Disease atherosclerosis atherosclerosis of aortic root 8.16E-03 GJA1 1
Cardiovascular Disease coronary disease coronary disease 8.49E-03 AKAP13, KCNJ12, LAMA4, PDE5A 4
Cardiovascular Disease cardiomyopathy cardiomyopathy 9.57E-03 GJA1, PDE5A 2
Cardiovascular Disease atherosclerosis atherosclerosis 1.11E-02 AKAP13, GJA1, LAMA4, PDE5A 4
Cardiovascular Disease patent ductus arteriosus patent ductus arteriosus 1.25E-02 PDE5A 1
Cardiovascular Disease left ventricular dysfunction left ventricular dysfunction 1.36E-02 PDE5A 1
Cardiovascular Disease intermittent claudication intermittent claudication 1.41E-02 PDE5A 1
Cardiovascular Disease ventricular fibrillation ventricular fibrillation 1.41E-02 KCNJ12 1
Cardiovascular Disease stroke stroke 1.44E-02 GJA1, PDE5A 2
Cardiovascular Disease valvulopathy valvulopathy 1.73E-02 PDE5A 1
Cardiovascular Disease cardiac arrest cardiac arrest 1.79E-02 PDE5A 1
Cardiovascular System Development and Function looping morphogenesis looping morphogenesis of heart 2.05E-02 GJA1 1
Organ Development looping morphogenesis looping morphogenesis of heart 2.05E-02 GJA1 1
Cardiovascular Disease chronic stable angina chronic stable angina 2.16E-02 KCNJ12 1
Organ Development gonadogenesis gonadogenesis 2.29E-02 GJA1, OR7C1 2
Cardiovascular System Development and Function contractility contractility of cardiomyocytes 2.32E-02 LAMA4 1
Cardiovascular System Development and Function morphogenesis morphogenesis of blood vessel 3.01E-02 GJA1 1
Cardiovascular Disease aortic stenosis aortic stenosis 3.07E-02 PDE5A 1
Cardiovascular Disease systemic sclerosis systemic sclerosis 3.07E-02 PDE5A 1
Cardiovascular Disease endothelial dysfunction endothelial dysfunction 3.12E-02 PDE5A 1
Cardiovascular Disease ischemic cardiomyopathy ischemic cardiomyopathy 3.44E-02 PDE5A 1
Cardiovascular Disease pulmonary hypertensive arterial disease pulmonary hypertensive arterial disease 3.54E-02 PDE5A 1
Cardiovascular Disease ventricular tachycardia ventricular tachycardia 3.86E-02 KCNJ12 1
Cardiovascular Disease preeclampsia preeclampsia 3.91E-02 PDE5A 1
Cardiovascular System Development and Function contractility contractility of heart 4.12E-02 PDE5A 1
Cardiovascular System Development and Function function function of heart 4.18E-02 LAMA4 1
Organ Development function function of heart 4.18E-02 LAMA4 1
Cardiovascular Disease coronary artery disease coronary artery disease 4.30E-02 AKAP13, LAMA4, PDE5A 3
Cardiac Arteriopathy coronary artery disease coronary artery disease 4.30E-02 AKAP13, LAMA4, PDE5A 3
Cardiovascular System Development and Function vasoconstriction vasoconstriction of blood vessel 4.54E-02 PDE5A 1
Cardiovascular Disease hypertension hypertension 4.55E-02 AKAP13, CDC27, PDE5A 3
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conservation of the expected amino acid in this position further supporting the importance of the 
change in amino acid sequence at this position (Figure 7). 
 
Figure 7.  BLAST alignment of LAMA4 across species. Aspartic Acid (D) at amino acid 879 is 
conserved. 
 
LAMA4 BED file: chr6 112,535,827 112,682,521 was submitted to UCSC liftOver 
(Hinrichs et. al. 2006) and the converted start and stop positions of the chromosome were 
returned. After translation to the latest build, the nucleotide coordinate 112,463,353 was used as 
search criteria to verify no SNP data is associated with this particular variant which would 
diminish the novel status. In 2221 NCBI SNPs for the LAMA4 gene there were no matches. 
SIFT analysis (Ng 2003) was repeated with the updated coordinates to ensure the novel 
and damaging status remained current. Chromosome coordinates 6,112463353,1,C/G were 
entered into the submission form. Output options included OMIM Disease and Allele Frequencies 
(All HapMap Populations). The SIFT score (0) predicted the amino acid substitution is damaging. 
No dbSNP ID, allele frequencies, or OMIM disease associations were reported.  
PolyPhen-2 (Polymorphism Phenotyping v2, Adzhubei et. al 2010) analysis was also 
repeated to ensure the amino acid change was still considered damaging. A score of 1.0 was 
returned confirming the damaging status. The multiple sequence alignment used in the PolyPhen-
2 pipeline, further confirms sequence conservation at this location (Figure 8). 
To further verify novelty of this variant, the Exome Variant Server (EVS) was queried 
and the variant was not found. The coordinates were expanded to look in the region flanking the 
variant of interest (4,875 alleles with data from this region) and remained novel (October 21, 
2011). This analysis was repeated in February 2012, when the data set had been updated to 5400 
exomes. There were no occurrences of the LAMA4 D879H variant in 7020 alleles of the 
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European cohort. One occurrence of this variant was identified in 1 of 3738 African American 
alleles that covered that region. No phenotype or clinical associations, known SNP IDs, or 
associated publications were assigned to this variant so it retains its novel and rare status (Exome 
Variant Server). 
 
Figure 8. PolyPhen-2 alignment of LAMA4. Results illustrate the conservation of aspartic acid at 
position 879. 
 
4.3.4 Laminin Alpha-4 Protein Modeling 
The cytosine to guanine nucleotide change results in a change in the amino acid 
sequence. The expected triplet GAT encodes a negatively charged aspartic acid (D). The 
occurrence of a cytosine in place of the guanine (CAT) encodes for histidine (H), which is a 
positively charged amino acid at neutral pH. Designing a homology model would be extremely 
interesting to determine if the D to H mutation causes any conformational changes in the protein, 
especially since PolyPhen-2 and SIFT analysis predict the variant to be damaging.  
No human model of laminin proteins is available. The G1 domain of mouse laminin 
alpha-2 is the most homologous to the G1 domain of human laminin alpha-4. The crystal 
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structure of the mouse LG1-3 region of the laminin alpha2 chain (PDB ID 2WJS) served as a 
backbone for the laminin-4 wild type and mutated models (Carafoli et. al. 2009).  
Blastp alignments were conducted to verify the sequence segment to utilize for the model 
(Figure 9). The procedure was repeated for the mutated model; aspartic acid was replaced with a 
histidine at amino acid 879 (Figure 10). The laminin alpha-4 sequence is based on the Blastp 
alignment of amino acids 875-1013 which encode part of the laminin G1 domain. The amino 
acids in the pdb file after amino 2324 were deleted to eliminate the G2 and G3 domains in the 
2WJS sequence, resulting in a more accurate depiction of the protein and simplifying the view of 
the end model. The MODELLER alignment algorithm (Altschul 1990) was used to generate the 
final sequence alignment of the human laminin alpha-4 and mouse laminin alpha-2 proteins.  
 
Figure 9.Blastp alignment of human wild type laminin alpha-4 to mouse laminin alpha-2 protein. 
 
Figure 10. Blastp alignment of human mutated (D879H) laminin alpha-4 to mouse laminin alpha-
2 protein.  
 
Homology modeling did not demonstrate significant structural changes between the wild 
type laminin alpha-4 protein and the mutated version (Figure 11).  The D879H coding change 
occurs in the G1 domain of the protein. In mouse, the laminin alpha-2 LG1 domain is 
hypothesized to offer a necessary protein surface for integrin binding. Large surface regions not 
blocked by carbohydrate modifications are present in the LG1 domain. The faces of the LG1 β –
sandwich are free of carbohydrates in the alpha chain of mouse (Carafoli et. al. 2009) and   the 
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virtual human model is expected to be free of carbohydrates as well, therefore capable of binding. 
Since this domain is suggested to act as an adhesive factor for endothelial cells (Lian et. al. 2006), 
it was proposed that this mutation could disrupt proper cell binding, leading to catastrophic 
effects on the base framework of the circulatory system and cardiogenesis. Although the general 
structure of the mutated model does not appear to be altered as compared to the wild type model, 
it is still formally possible that the cell binding process is disrupted.  
The laminin alpha-4 mutation is 40 bases from the proposed binding site amino acids 
919-1207 (Gonzales 2002) and points out into solution. Depending on the pH, the histidine will 
express a negative or neutral charge. The change from the negative aspartic acid to the neutral or 
positive histidine could affect binding or structure.  The mutation could lead to the formation of 
salt bridges with lysine or histidine or arginine within that sequence, potentially altering the 
structure. A change in the charge could remotely affect binding interactions. Without the 
availability of a crystal structure it is difficult to ascertain if any of these rearrangements is 
actually taking place.  
 
Figure 11. Homology models of laminin alpha-4 protein. (a) wild-type (b)D879H mutation 
mapped to the wild-type model (c) overlay of wild-type and mutated models. 
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This structural analysis, however, does not invalidate the potential connection that this 
variant may have with the HLHS pathway. It is difficult to analyze the impact of the LAMA4 
mutation because the crystal structure of the human protein has not been solved. This homology 
model serves as a proposal of the protein and does not indicate this specific mutation causes 
structural differences between the two models.   
4.4. LAMA4 and GJB2 Relationship - Pathway Analysis 
GeneMANIA (Warde-Farley et. al. 2010) was employed to examine potential physical 
interactions of LAMA4 and GJB2. LAMA4 and GJB2 were queried with GO biological function 
based weighting. GeneMANIA provided evidence of physical interactions between the two genes 
mediated by DAG1 and CAV1 (Figure 12). DAG1 is a laminin binding component of the 
dystrophin-glycoprotein complex (Stelzer et. al. 2012). The interaction of LAMA2 and DAG1 
has been well described. Caveolin1 (CAV1) interacts directly with G-protein alpha subunits and 
can functionally regulate their activity (Stelzer et. al. 2012). It is highly expressed in the vascular 
endothelium and to a lesser extent in cardiac fibroblasts and smooth muscle. CAV1 knockout 
mice express cardiac hypertrophy and left ventricular dilation and dysfunction. The heart of 
CAV1 knockout mice exhibit evidence for endothelial dysfunction as well (Krieger et. al. 2010). 
The LAMA4-DAG1-CAV1-GJB2 physical interaction was heavily weighted based on 
the supporting reference data. The interaction between LAMA4 and DAG1 is supported by iRef-
MINT and iRef - small scale studies sources. The DAG1 CAV1 interaction is supported by 
evidence from BioGRID small scale studies and iRef-small scale studies.  BioGRID small scale 
studies, iRef -HPRD, iRef -OPHID, and iRef - small scale studies provide evidence of the 
interaction between CAV1 and GJB2. DAG, CAV1, and GJB2 are involved in cell-cell junction 
assembly. LAMA4 and DAG1 interactions are more closely related through ECM and basement 
membrane functions. DAG1 and CAV1 interactions involve protein maintenance and cell –cell 
junction assembly, as does GJB2.  
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Figure 12: Physical interactions of Human LAMA4 and GJB2. GeneMANIA query results. The 
queried genes demonstrate direct and indirect  physical interactions suggesting they may be 
involved in related biological processes. This is further supported by the common functions such 
as cell-cell junction organization, cell-cell junction assembly, and maintenance of protein 
locations shared by some genes in the network.  
 
LAMA4, GJB2, GJA1, DAG1, and CAV1 were queried under similar conditions to 
determine if an obvious relationship was present that could be related associated to HLHS. 
Indirect physical interactions were present and well supported (Figure 13). A query for pathway 
relationships did not connect all genes involved unless the number of returned genes was 
expanded to 100 suggesting a distant relationship or a missing link between the two main groups 
and excluding GJB2 (Figure 14).   
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Figure 13.  GeneMANIA analysis of LAMA4, GJB2, DAG1, CAV1, and GJA1 relationships. 
The queried genes demonstrate direct and indirect physical interactions suggesting they may be 
involved in related biological processes.  
 
Figure 14. GeneMANIA analysis of GJB2, LAMA4, GJA1, DAG1, and CAV1. Network 
analysis shows extending the number of returned genes to 100 does not strongly connect all 
queried genes. Based on this analysis it is unlikely that together they are involved in the 
development of HLHS. 
 
4.5 LAMA4 and GJB2 Relationship - Family Pedigree 
 
The subject family is comprised of three sons. A history of cardiac anomalies on the 
maternal side has been documented.  One of the sons does not carry any congenital heart defect 
(labeled as ‘unaffected sibling’). One of the sons (labeled as ‘proband’) is affected by a serious 
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congenital heart defect known as hypoplastic left heart syndrome (HLHS).  A daughter who did 
not survive due to a spontaneous abortion (fetal demise) also was affected by HLHS (labeled as 
‘fetus’). The DNA of the parents and these offspring were available at the onset of the study. 
The DNA of another son became available later in the study. This child is affected with a 
longer than normal QT. A deaf phenotype caused by a deletion in the Connexin 26 (GJB2) gene 
is also present on the maternal side of the family. This child has a homozygous deletion in this 
gene and therefore expresses the deaf phenotype.  
Sequencher DNA analysis indicated that both the father and mother are heterozygous for 
the deletion. The non-HLHS child is homozygous for the deletion and thereby expresses the deaf 
phenotype (Figure 15). The mother and non-HLHS child both are affected by non-HLHS cardiac 
abnormalities. It is unknown if the maternal grandmother also expresses a CHD phenotype. 
Perhaps some protection is created by the GJB2 deletion leading to less severe forms of CHD, 
however further experimentation will need to be conducted to verify this suggestion. 
 
Figure 15. Family pedigree chart. Family members screened for LAMA4 and GJB2 by Sanger 
sequencing are indicated by the identification number under the nodes. Proband is indicated by *.  
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CHAPTER 5. CONCLUSION AND FUTURE DIRECTIONS 
The evidence presented in this thesis suggests the D879H variant in LAMA4 is involved 
in the development of HLHS. Mutation predictors SIFT and PolyPhen-2 suggested that the amino 
acid change is damaging and novel. The expected amino acid is highly conserved across species 
implying that it is important to the function of the protein. Furthermore, all immediate family 
members that carry the mutated version of the allele exhibit a form of cardiac abnormalities.  
Scientific literature indicates that the protein is expressed in the cardiovascular system 
during heart development and in the adult aorta. If HLHS in fact develops as a result of 
embryonic alterations in blood flow variations, this could indicate that LAMA4 is a culprit in the 
pathology of this syndrome.  Losses of integrin binding during embryonic development affecting 
the shape of cardiomyocytes and subsequent changes in ventricle morphology would support this 
hypothesis due to the implications these changes would have on blood flow. Mouse knockout 
studies further support the importance of LAMA4 in the cardiovascular system and heart function 
by the appearance of leaky vasculature, premature death due to cardiac dysfunction, and the 
changes in cardiomyocytes and incidence of cardiomyopathy. 
Homology modeling did not provide strong evidence that this particular mutation is 
causative. However, until the human structure is crystallized it is difficult to determine how 
accurate the model is. A model including the other LAMA4 non-novel variants found in the 
exome sequencing data may provide sufficient evidence to determine the inclusion of all the 
variations in this gene lead to an overall conformational change. The proposed structural effect 
could cause a disruption in protein binding leading to poor interaction of endothelial cell and 
cardiomyocytes with the extracellular matrix which could contribute to cardiomyopathy and 
compromised vasculature related to HLHS. 
Pathway analysis indicates that LAMA4 interacts with genes such as PRKCA and 
AKAP13which have known cardiac associations. Perhaps examining only the variants with 
novel, nonsynonymous, and damaging characteristics is too limiting to determine the cause of this 
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syndrome. The indirect relationship of LAMA4 and GJA1 is interesting as GJA1 is described in 
the arrhythmogenic right ventricular cardiomyopathy pathway (ARVC). The suggested 
interaction with DAG1 is also promising as the KEGG database indicates it is involved with 
laminin in the Hypertrophic cardiomyopathy (HCM),  Dilated cardiomyopathy (DCM), and Viral 
myocarditis disease pathways (Kanehisa et. al. 2000, 2012).  
The relationship of AKAP13 and LAMA4 also may worthwhile of further exploration. 
Perhaps the coupling of mutations in these genes contributes to the development of HLHS. Three 
of the four children that carry both the LAMA4 and AKAP13 variants, two are diagnosed with 
HLHS, and the other has a longer than normal QT, possibly indicating dominant inheritance of 
the variant and reduced penetrance of the phenotype.  IPA pathway analysis of the original 
variant list indicates that AKAP13 is related to cardiovascular disease and most specifically 
cardiac hypertrophy. AKAP13 is involved in a cellular response known as pathological cardiac 
hypertrophy. This syndrome includes increased cardiomyocyte size and greater organization of 
the sarcomere (Carnegie et. al. 2008). Since cardiomyocytes provide the foundation of 
sarcomeres which are responsible for heart contraction, mutations in these genes could affect 
blood flow. Interestingly DAG1 and CAV1 are members of subsarcolemmal complexes involved 
in contraction through supporting organ architecture, transmitting force between cells, and signal 
transduction pathways (Ahmad 2005). PRKCA is also involved in this pathway.  GeneMANIA 
analysis indicated LAMA4 has a direct pathway connection to both PRKCA and AKAP13. 
PRKCA and AKAP13 have a direct physical interaction (Figure 4.) and their functional 
biological relationship has been well described (Carnegie et. al. 2004, Ahmad et. al. 2005). If 
HLHS is indeed due to an alteration in blood flow during embryogenesis, perhaps the combined 
effect of the mutations in these three genes is significant in this patient. 
DNA sequencing combined with physical interaction analysis suggests that there may be 
an indirect relationship between hearing impairment caused by a deletion in GJB2, the D879H 
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mutation in the LAMA4 gene, and CHD. However, since neither of the HLHS children carry the 
GJB2 deletion, it is not possible to conclude this relationship is specific to HLHS. Additionally, 
the relationship is based on physical evidence that does not necessarily imply that the interactions 
are part of a biological pathway of the syndrome. The hypothesis cannot totally be discarded 
because even though the proteins are not known to interact at this time does not definitively mean 
the interaction is not possible. Research has suggested that there are links between hearing 
impairment and cardiac dysfunction, therefore the relationship of GJB2 to HLHS may not have 
been uncovered as of yet. Further investigation of these relationships may link these mutations to 
the development of CHD or reveal that the GJB2 deletion modulates the severity of CHD. This 
hypothesis is corroborated by evidence that the mother and one of the children do not show 
HLHS, and they are both positive for the LAMA4 variant and a deleted GJB2 allele.  
Additional analysis such as binding and expression assays will be useful to further 
determine the involvement of the LAMA4 mutation in regards to HLHS. The inclusion of genes 
such as PRKCA, AKAP13, DAG1, GJB2, and CAV1 may result in a more in-depth 
understanding of the potential physical or pathway interactions. It also may prove worthwhile to 
compare pathway analysis of Osteogenesis Imperfecta (a connective tissue disorder related 
collagen, another integral basement membrane protein. Belmont et. al. 2011) with HLHS to 
further investigate the relationship between expression of the deaf phenotype and CHD in this 
family. 
The systematic approach implemented in this study serves as an efficient and effective 
guideline to conduct unique variant detection in relationship to disease. Integrating genomic and 
proteomic methods along with the application of bioinformatic tools provides ample information 
to draw conclusions about the relationships of variants and the syndrome under investigation in 
an efficient and effective manner.  
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